The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
A research and development overview of Fingolimod
Author(s): 
Pages: 683-687,698
Year: Issue:  12
Journal: Qilu Pharmaceutical Affairs

Keyword:  FinglimodMultiple SclerosisImmunomodulator;
Abstract: Fingolimod(FTY720),a novel immunomodulator agent,is developed from ISP - I,which is a secondary metabolites of fungi. It was approved by FDA in 2012 for the treatment of autoimmune disease multiple sclerosis. Unlike the traditional immunosup-pressive agents,fingolimod exerts immunosuppressive and immunoregulatory functions mainly through interaction with shhingosine - 1 -phosphate(S1P)receptors on the cell surface without affecting activation and proliferation of lymphocyhtes. This article briefly reviewed the development process of fingolimod,elaborate the structural optimization and transformation,in order to provide experience for chemi-cal rsearch.
Related Articles
No related articles found